The prognosis of patients w-ith malienant tumours is impaired xxith metastatic dissemination of the disease. Despite adxances in diagnostic and therapeutic approaches. 30-40% of patients w-ith colorectal cancer undergoinc curative resection for primary neoplasm dexelop local or distant tumour relapse during follow--up. which carries a high probability of death (Borinc et al. 1993: Safi and Bever. 1993) .
Metastasis is a multistep process involving numerous host-tumour interactions. in xA hich haematogenous spread of cancer cells from the primary tumour constitutes a key point (Liotta and Stetler-Stexenson. 1991) . Investigations devoted to studv this subpopulation of circulating, malignant cells have been limited until the advent of the reverse transcriptase polI merase chain reaction (RT-PCR) (Johnson et al. 1995) . Usinc this approach and targeting tissue-specific gene transcription. it has been possible to identify circulatinc cancer cells in patients xxith different neoplasms (Smith et al. 1991 : Moreno et al. 1992 : Tada et al. 1993 : Hillaire et al. 1994 . including colorectal cancer (Hardingham et al. 1995 : Jonas et al. 1996 : Denis et al. 1997 Nakamori et al. : Wonc et al. 1997 .
With regard to the detection of circulating tumour cells in colorectal cancer. sex-eral aspects need to be clarified. In that sense.
Received 17 November 1997 Revised Accepted 1 Apnl 1998 Correspondence to: A Castells. Gastroenterology Department. Hospital Clinic Provincial. Villarroel 170. 08036 Barcelona. Catalonia. Spain the lack of an extensive control group (Denis et al. 1997 : Nakamonr et al. 1997 : Wong et al. 1997 or the inclusion of onlx patients wxith colorectal lixer metastases (Jonas et al. 1996) preclude an appropriated assessment of both accuracv of this method and the relationship betx-een presence of circulating malignant cells and tumour stage.
The present study A as aimed at assessinc the presence of colonic cells in peripheral blood of colorectal cancer patients by means of RT-PCR targeted to carcinoembryonic antigen (CEA) mRNA. After confirming in vitro sensitixity-in a recoverx expenment. a large series of colorectal cancer patients in different evolutionarv stages and a control group includinc not onlv healthv subjects but also patients with other gastrointestinal disorders w ere analy sed. In this regard. inclusion of a subset of patients with inflammatorx bowxel disease is especially noteworthx because it represents a well-characterized non-neoplastic local injury. Finallv. the effect of remox ing, the primarv tumour on circulating neoplastic cells A-as also investigated in a subgroup of cases submitted to surgical resection.
PATIENTS AND METHODS Patients
Betx een October 1995 and September 1996. 95 consecutive patients with histologically confirmed primary colorectal cancer were included in the study. The median age wxas 69 y-ears (range 25-93x).with 60 men and 35 w-omen. According to the TNM system (Intemational Union Against Cancer). six patients were classified in stage I. 32 in stage II. 37 in stage III and 20 in stagye IV 
Reverse transcriptase and polymerase chain reaction
Rexerse transcriptase (RT) reaction xwas prepared in a final volume of 20 gl and contained 4 gl of total RNA. 4 pl of RT 5x buffer (Tris-HCl 250 mmol 1-') pH 8.3. potassium chloride 250 mmol 1-1. magnesium chloride 50 mmol 1-1. dithiothreitol (DTT) 50 mmol 1-'. spermidine 2.5 mmol 1-'). 1.5 tl magnesium chloride (50 mmol 1-1. Gibco-BRL). 2 gi deoxynucleotide triphosphates (dNTPs) (10 mmol 1-1 each). 1 gl random primer (500 gag ml-'. Promeaa). 0.5 pg RNAsin (40 U ml-'. Promega). 5 PI distilled w ater and 2 pl AMV (axvian mveloblastosis vinus) reverse transcriptase (5 U ml-'. Promega). RT reaction was incubated at 42 C for 45 min followed by a 5-min period at 95"C to inactix-ate the rex erse transcriptase. CEA-specific oligonucleotide primers xere synthesized according, to published sequence information (Schrewe et al. 1990 ):
CNC 1: 5'-TCCATCTCCAGCAACAACTCC-3' (sense) and CNC2: 5'-AAAGTCCCATTGACAAACCAA-3' (anti-sense). Primers were selected to span an intron. to synthesize different-sized amplification products from the CEA mRNA (388 bp) and any contaminating genomic DNA (approximately 1020 bp). A schematic representation of the CEA primer positions is shown in Fiaure 1.
RT solution (2.5 pg) was diluted in a final xolume of 50 gl of PCR reaction mixture which contained 5 gl PCR lOx buffer (Tris-HCI 200 mmol 1-' pH 8.4. potassium chloride 500 mmol 1-1).
1 pg d-NTPs (2 mmol 1-1 each). 2.5 gl of each CEA gene pnrmer (20 jamol 1-'). 0.5 pg Taq polymerase (5 U ml-l. Gibco-BRL) and distilled water to 50 p1. Samples were overlaid w-ith mineral oil and then heated at 94°C for 3 min. Cycle conditions were: 94-C for 30 s. 62-C for 1 min. 72°C for 1 mn. for 35 cycles. PCR was completed with a penrod of 5 mmn at 720C.
Samples were electrophoresed on 2%7 agarose gels and xisualized bx ethidium bromide staining.
To ensure that bands correspond to CEA cDNA. a restriction diaest usina enzymes PstI. HhaI and RsaI w as performed.
Integrity of the RNA obtained from clinical samples wxas confirmed by determining the presence of glyceraldehyde phosphate dehydrogenase (GAPDH) m_RNA in the same samples. using pnmers GI: 5'-CCATGGAGAAGGCTGGGG-3' (sense) and G2: 5'-CAAAGTTGTCATGGATGACC-3' (anti-sense).
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The study A-as performed in a blinded fashion. so that patients' clinical characteristics w ere unknown by the investigator performing RT Circulating colonic cells in colorectal cancer 1371 in those in whom neoplastic dissemination was ruled out [12/17 (71%) vs 3n (43%) respectively; P = 0.1].
All cases demonstrated satisfactory RNA quality by a control PCR amplification of GADPH mRNA (Figure 3) . No inconsistent results were obtained when repeating the analysis in the same sample.
DISCUSSION
The results of the present study confirm that CEA mRNA can be detected in the peripheral blood of patients with colorectal carcinoma by means of RT-PCR. In this setting, the detection of CEA mRNA is very probably associated with the presence of circulating tumour cells on the basis of the following considerations:
(1) the frequency of CEA mRNA positivity correlated with tumour stage; (2) CEA mRNA expression disappeared after surgical resection of the primary tumour in most of the non-metastatic colorectal cancer patients; (3) serum CEA concentration correlated with CEA mRNA positivity; and (4) healthy volunteers had undetectable CEA mRNA in the blood. Additionally. the recovery experiment indicated a clear correlation between CEA mRNA expression and tumour cell concentration. In this regard, although it cannot be assumed that the detection threshold in all clinical samples was identical to that in the recovery assay (O'Sullivan et al, 1995) , results obtained in colorectal cancer patients and healthy volunteers indicate that specificity of our approach seems to be adequate for its purpose. Nevertheless, false-negative results could not be definitively ruled out.
Several reports have demonstrated that PCR is a useful tool for the detection of circulating cancer cells in solid tumours (Johnson et al, 1995) . In gastrointestinal tumours, in which cancer-specific mutations in DNA have not yet been found, it is necessary to use reverse transcriptase to prepare cDNA from peripheral blood mRNA for identifying tissue-specific gene expression. Detection of occult neoplastic cells in patients with colorectal cancer has been carried out using different targets. K-ras mutations have been reported as a useful marker when samples of the primary tumour are available to confirm the mutation (Hardingham et al, 1995) .
Cytokeratins, a multigene family of proteins with differentiationassociated patterns of expression (Moll et al, 1982) , have also been used to characterize neoplastic cells of epithelial origin in bone marrow (Lindemann et al. 1992) and peripheral blood (Denis et al, 1997; Nakamori et al, 1997; Soeth et al, 1997) . However, most of them are found in samples of healthy subjects, thus limiting their suitability as targets (Burchill et al, 1995) . CEA was chosen as a target because it is a cell-surface molecule constitutively expressed in the colonic epithelial tissue. and its expression is maintained in almost all colorectal carcinomas (Shively and Beatty, 1985) . Its genomic organization (Schrewe et al, 1990) and cDNA sequence (Oikawa et al, 1987) are known. In addition, this target has been used in the specific detection of CEA-expressing tumour cells in bone marrow aspirates (Gerhard et al, 1994) and, recently, in the identification of circulating neoplastic cells in patients with colorectal liver metastasis (Jonas et al, 1996) .
From a clinical point of view, the present study documents limitations on both the sensitivity as well as the specificity of the assay, thus probably restricting the diagnostic usefulness of this technique in colorectal cancer. In that sense, CEA mRNA could be detected in patients with oter gastrointestinal neoplasms expressing CEA as it was expected, and in those with inflammatory bowel disease. By contrast, not all colorectal cancer patients, including those with stage IV disease. had detectable CEA mRNA expression. This fact probably reflects that tumour cells are circulating in clusters (Liotta and Stetler-Stevenson, 1991) . thus favouring a bias in the collection of blood samples. According to this suggestion. the true prevalence of circulating cancer cells is likely to be much higher than that detected by a single blood extraction.
In contrast, the presence of circulating tumour cells is expected to be associated with a poor prognosis (Hardingham et al, 1995) .
in a similar manner to micrometastatic tumour cells in bone marrow (Lindemann et al. 1992; Soeth et al, 1997) . Results of the present investigation suggest that circulating neoplastic cells correlate with the presence of distant metastasis at inclusion. However, it should be emphasized that a high proportion of nonmetastatic colorectal cancer patients (stages I-HI) were positive for CEA mRNA expression, even after surgery. Then, clinical relevance of this finding remains uncertain at present. Considering metastasis is believed to be an inefficient process (Liotta and Stetler-Stevenson, 1991) , evidence of circulating tumour cells could represent an irrelevant clinical event. On the contrary. if their presence had prognostic implications, detection of malignant cells in peripheral blood may improve tumour staging and help to identify those patients who would benefit from systemic therapy after surgery. Accordingly, the presence of circulating cancer cells should be considered either as a marker of metastatic potential or evidence of residual disease, and redefinition of remission status could be needed. Long-term follow-up of these patients will allow us to establish its clinical relevance.
In the present study, a significant proportion of patients with inflammatory bowel disease had detectable CEA mRNA expression in the blood, the significance of this finding being unclear. Illegitimate transcription by white blood cells or epithelial contamination of samples with a small number of skin cells because of the venepuncture cannot be formally excluded, but the absence of expression in healthy subjects made this possibility very unlikely. Circulating CEA mRNA caused by cytolysis is improbable because of large amounts of RNAases (Hillaire et al, 1994) . Although up-regulation of CEA gene family members in granulocytes of patients with inflammatory bowel disease has not been described yet, the feasibility of this hypothesis cannot be ruled out.
However, considering that this disease involves necrosis of the colonic epithelium, CEA mRNA expression suggests the presence of non-neoplastic epithelial colonic cells in peripheral blood. A similar event has been shown among patients with non-malignant disease submitted to surgical resection or liver transplantation in whom peripheral alpha-fetoprotein mRNA expression was detected after surgery (Lemoine et al, 1997) . Unfortunately. the low sensivity of both direct microscopy and immunocytochemistry in this setting (Leather et al, 1993; Wong et al, 1995) precludes the distinction of both cellular subtypes and, therefore, a definitive assessment of the origin of CEA mRNA expression in patients with inflammatory bowel disease.
In summary, the results of the present investigation confirm that it is possible to amplify CEA mRNA in the peripheral blood, its presence in colorectal cancer patients being almost certainly derived from circulating neoplastic cells. Correlation of this cellular subpopulation with the occurrence of distant metastasis at inclusion suggests a possible role of this method in improving cancer staging. Nevertheless, CEA mRNA detectable in blood of patients with inflammatory bowel disease probably indicates the presence of non-neoplastic epithelial colonic cells. Therefore.
CEA mRNA expression would indicate the loss of cell adhesion in colonic epithelium because of either neoplastic or inflammatory processes.
